Oral relugolix NDA accepted for Priority Review by FDA

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Myovant Sciences’ New Drug Application for once-daily, oral relugolix (120 mg) for the treatment of men with advanced prostate cancer has been accepted for Priority Review by FDA.

“As recently published in the New England Journal of Medicine, relugolix demonstrated superior efficacy and a 54% lower risk of major adverse cardiovascular events compared to the current standard of care, leuprolide acetate injections, in the Phase 3 HERO study,” Lynn Seely, chief executive officer of Myovant Sciences, said in a statement.

FDA has set a target action date of December 20, 2020 under the Prescription Drug User Fee Act. In its acceptance letter, the FDA also stated that it is currently not planning to hold an advisory committee meeting for this application. If approved, relugolix would be the first and only oral gonadotropin-releasing hormone receptor antagonist treatment for men with advanced prostate cancer.

Table of Contents

YOU MAY BE INTERESTED IN

Congress settled the FY26 question in February, with NCI receiving $7.352 billion, an increase of $128 million over the prior year. After a year in which cancer center directors spent an extraordinary share of their leadership attention defending the research enterprise, that outcome deserves to be called what it was: a win.
Harold P. Freeman, a surgeon who started his career in Harlem, where, in addition to performing surgeries, he pioneered the system of patient navigation, and who studied health disparities and served as president of the American Cancer Society and chair of the President’s Cancer Panel, died on Aug. 11. He was 93.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login